404010-84-0 Usage
Uses
Used in Medicinal Chemistry:
Methyl 2-amino-4-morpholinobenzoate is used as a compound in medicinal chemistry for its potential interactions with biological systems, which could contribute to the development of new drugs or therapeutic agents.
Used in Organic Chemistry:
Methyl 2-amino-4-morpholinobenzoate is used as a compound in organic chemistry for its structural properties, which may facilitate the synthesis of other complex molecules or contribute to the understanding of chemical reactions involving similar structures.
Used in Drug Development:
Methyl 2-amino-4-morpholinobenzoate is used as a potential candidate in drug development due to its structural features that may allow it to interact with biological targets, potentially leading to the creation of new pharmaceuticals.
Used in Pharmacological Research:
Methyl 2-amino-4-morpholinobenzoate is used as a research tool in pharmacological studies to explore its interactions with biological systems and assess its potential as a therapeutic agent or a lead compound for further development.
Check Digit Verification of cas no
The CAS Registry Mumber 404010-84-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,4,0,1 and 0 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 404010-84:
(8*4)+(7*0)+(6*4)+(5*0)+(4*1)+(3*0)+(2*8)+(1*4)=80
80 % 10 = 0
So 404010-84-0 is a valid CAS Registry Number.
404010-84-0Relevant academic research and scientific papers
Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors
Fan, Jun,Dai, Yang,Shao, Jingwei,Peng, Xia,Wang, Chen,Cao, Sufen,Zhao, Bin,Ai, Jing,Geng, Meiyu,Duan, Wenhu
supporting information, p. 2594 - 2599 (2016/05/09)
Fibroblast growth factor receptors (FGFRs) are important oncology targets due to the dysregulation of this signaling pathway in a wide variety of human cancers. We identified a series of pyrazolylaminoquinazoline derivatives as potent FGFR inhibitors with low nanomolar potency. The representative compound 29 strongly inhibited FGFR1-3 kinase activity and suppressed FGFR signaling transduction in FGFR-addicted cancer cells; FGFRs-driven cell proliferation was also strongly inhibited regardless of mechanistic complexity implicated in FGFR activation, which further confirmed that 29 was a potent pan-FGFR inhibitor. The flexibility of our structure offered the potential to preserve good affinity for mutant FGFR, which is important for developing TKIs with long-term efficacy.
